Investment Committee

Neil Johnson is a member of the Investment Committee, an Executive Director and Duke Royalty’s Chief Executive Officer with responsibility for the overall strategic direction and performance of the company. Working closely with the other Board members and the Investment Committee, he leads all deal origination, due diligence and structuring. 

Mr. Johnson has over 20 years of experience in investment banking, merchant banking, and research analysis in both the Canadian and UK capital markets. In 2012 he co-founded and became Chief Executive Officer of Difference Capital Financial, a Canadian publicly listed merchant bank. For the previous 19 years he worked for Canaccord Genuity, first in Canada and later at Canaccord London rising to the positions of Head of Corporate Finance (Europe), Global Head of Technology, and a member of the Global Executive Committee. Mr. Johnson was instrumental in the firm becoming authorised as a nominated adviser for AIM and regulated in the UK and London Stock Exchange Main Market listings; he spearheaded the firm's diversification into the technology industry, and led Canaccord’s initiative to attract North American firms to list in London. 

During his tenure the Canaccord European operation grew revenues from less than £5 million to over £50 million, completed over 100 transactions and raised in excess of £3 billion for North American companies listed in London.  

Mr. Johnson is a graduate of the Richard Ivey School of Business at the University of Western Ontario and holds the designation of Chartered Financial Analyst Charterholder.

Image result for linkedinLinkedin



Justin Cochrane is a member of Duke Royalty's Investment Committee and Executive Vice President of Corporate Development. He is responsible for helping direct Duke Royalty's business strategy and leads all business development efforts.

Prior to joining Duke Mr. Cochrane was the Executive Vice President of Corporate Development Sandstorm Gold Ltd. At Sandstorm, Mr. Cochrane was responsible for sourcing, negotiating and executing royalty and stream financing transactions across the globe. Mr. Cochrane was a key part of Sandstorm's team as it grew into one of the largest royalty and stream financing companies in Canada. Prior to Sandstorm Mr. Cochrane was a Vice President at National Bank Financial where he spent some nine years working in the investment banking group. As Vice President, Mr. Cochrane managed primary coverage of BC based clients in the diversified, paper & forest products, power & utilities, resources, cleantech and other sectors. Mr. Cochrane specialised in providing advice to clients on merger and acquisition transactions and equity and debt financing opportunities.

Mr. Cochrane holds the designation of Chartered Financial Analyst Charterholder and received a Bachelor of Commerce degree, with honours, from the University of British Columbia, Vancouver, Canada. Mr. Cochrane is a government ambassador at the Multiple Sclerosis Society of Canada and also a director of Antipodes Gold Limited.

Mr. Cochrane is employed by Abingdon Capital Corporation which has a support services contract with Duke Royalty Limited. 

Image result for linkedinLinkedIn


Jim Webster is a member of the Investment Committee and is Duke Royalty’s Chief Investment Officer, with responsibility to oversee the due diligence and negotiations on prospective investment opportunities for the Company; direct the execution of royalty transactions approved by the Duke Royalty board; and monitor royalty investments made by the Company.

Prior to joining the Company, between 2003 and 2009, as Managing Partner and Chair of the Investment Committee for Capital Royalty Partners LLC (now CRG L.P.), Mr. Webster was instrumental in raising $325 million for the firm’s first fund. In his capacity as Chair of its Investment Committee, he led due diligence and negotiations on royalty interests for the firm. Today, CRG L.P. has approximately $2 billion under management. 

Between 1993 and 2002, from virtually the inception of Drug Royalty Corporation Inc, Mr. Webster was a senior member of the world’s first public pharmaceutical based royalty company, listed on the Toronto Stock Exchange. Mr. Webster served in various capacities including President, Chief Executive Officer, and Chairman of its Investment Committee and oversaw the firm’s growth from its startup phase through to its eventual sale in 2012 for C$133m. At Drug Royalty Corporation Inc, he identified, assessed and negotiated investments in the pharmaceutical and biotechnology sectors. The company (now DRI Capital Inc) continues to be a leading royalty investor, with over $3 billion under management.

Mr. Webster holds a Masters of Business Administration from the Richard Ivey School of Business, and is also a CFA Charterholder and a Canadian Professional Accountant of Canada. He also completed the Columbia Executive Management Program in New York.

David Campbell is a member of the Investment Committee and is a Partner in the Health & Life Sciences practice of Oliver Wyman. He works with the Duke board in relation to the identification, analysis and acquisition of certain royalty interests under the exclusive collaboration between Oliver Wyman and Duke Royalty.

Mr. Campbell has worked extensively with pharmaceutical and biopharma companies, academic research agencies, hospitals, and clinics, as well as providers to and investors in these industries for the past 20 years. He has addressed conferences of healthcare executives in both North America and Europe. He co-authored Beyond the Blockbuster, Licensing to Win and Beyond a Shadow of a Drought,  three white papers on the state of the biopharma industry's licensing and R&D opportunities. He has advised clients and governments on more than $US1.4 Billion in royalty-related transactions in the biopharma and healthcare space in North America, Europe and Asia, for both high-income and developing world opportunities. 

Prior to joining Oliver Wyman, Mr. Campbell practised strategy consulting with another global management consultancy.

Mr. Campbell holds an Honours Bachelor of Applied Science in Electrical Engineering from Queen’s University, where he co-developed a biomedical device for neuro-muscular disease diagnoses as his engineering thesis.

Andrew Chadwick-Jones is a member of the Investment Committee and is a Partner at Oliver Wyman’s London office, specialising in health delivery systems. He works with the Duke board in relation to the identification, analysis and acquisition of certain royalty interests under the exclusive collaboration between Oliver Wyman and Duke Royalty.

Mr. Chadwick-Jones has been at Oliver Wyman for 20 years and in that time has worked on over 150 client engagements. His areas of focus are innovation in new integrated care models and their adoption by providers and implications for payers; performance improvement in hospital systems and public-private partnerships (often between new entrants and the NHS). 

Prior to joining Oliver Wyman in 1995, Mr. Chadwick-Jones won an exhibition scholarship at Christ Church, Oxford University, where he holds a BA and MA in Biological Sciences.

Delivered by Investis – link to website (opens in a new window)